Autres langues Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
3,3 ^USD	-2,37%		-6,52%	-54,79%

26/06	Repare Therapeutics annonce que le lunresertib associé à Folfiri montre une efficacité et une tolérance "prometteuses" dans une étude de phase 1 sur les tumeurs solides	MT
26/06	Repare Therapeutics Inc. annonce à l'ESMO GI les premiers résultats positifs de l'essai clinique de phase 1 MINOTAUR évaluant le lunresertib en association avec FOLFIRI	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study	26/06
Repare Therapeutics : Initial Data from Phase 1 MINOTAUR Clinical Trial – Combination with FOLFIRI	26/06
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI	26/06
Repare Therapeutics Inc. Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI	26/06
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib	13/06
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib	12/06
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion Trial	10/06
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial	10/06
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of Tresr Clinical Trial	10/06
Repare Therapeutics : Corporate Presentation	10/06
Repare Therapeutics Gets Fast-Track Designation for Cancer Treatment Combo Candidate	04/06
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer	04/06
Repare Therapeutics Inc. Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer	04/06
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	03/06
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024	29/05
Top Premarket Gainers	08/05
Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	08/05
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results	07/05
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
DEBIOPHARM AND REPARE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL COMBINATION OF WEE1 AND PKMYT1 INHIBITION	01/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Autres langues

Filtres